Document is current
Any future updates will be listed below
-
Authors
Grassl, Niklas https://orcid.org/0000-0001-7987-0444
Poschke, Isabel https://orcid.org/0000-0002-4387-5566
Lindner, Katharina https://orcid.org/0000-0002-2735-3266
Bunse, Lukas https://orcid.org/0000-0002-4490-7574
Mildenberger, Iris
Boschert, Tamara https://orcid.org/0009-0007-8957-5319
Jähne, Kristine
Green, Edward W.
Hülsmeyer, Ingrid
Jünger, Simone
Kessler, Tobias
Suwala, Abigail K.
Eisele, Philipp
Breckwoldt, Michael O. https://orcid.org/0000-0002-9980-2390
Vajkoczy, Peter
Grauer, Oliver M. https://orcid.org/0000-0003-4279-4497
Herrlinger, Ulrich
Tonn, Joerg-Christian
Denk, Monika
Sahm, Felix https://orcid.org/0000-0001-5441-1962
Bendszus, Martin
von Deimling, Andreas https://orcid.org/0000-0002-5863-540X
Winkler, Frank
Wick, Wolfgang https://orcid.org/0000-0002-6171-634X
Platten, Michael https://orcid.org/0000-0002-4746-887X
Sahm, Katharina https://orcid.org/0000-0001-7694-0988
-
Funding
Funding for this research was provided by:
Gemeinnützige Hertie-Stiftung (P1200013)
Deutsche Forschungsgemeinschaft (445549683, SFB1366-TPC01, 39404578, 404521405, SFB1389-TPB06, EB 187/8-1, 404521405, SFB1389-TPB06, 445549683, 39404578, GRK2727-TPB1.1, SFB1389-TPB01)
Deutsche Krebshilfe (70113456, 70113456)
Helmholtz Institute for Translational Oncology HI-TRON
Helmholtz International Graduate School
Baden-Württemberg Stiftung (BWST_ISF2018-046, BWST_ISF2018-046)
Rolf Schwiete Foundation
Helmholtz Institute for Translational Oncology HI-TRON Rolf Schwiete Foundation
- License Information
-
More Information
Article History
Received: 23 February 2023
Accepted: 22 August 2023
First Online: 21 September 2023
Competing interests
: M.P. and E.W.G. are founders of Tcelltech and inventors of associated intellectual property related to glioma-reactive T cell receptors (patent no. WO2022200456A1). M.P. and W.W. are inventors of associated intellectual property related to IDH1R132H vaccine (patent nos. EP2800580B1 and US10161940B2). M.P., K.S. and L.B. are inventors of associated intellectual property related to H3K27M vaccines (patent nos. EP3118217A1 and US20180155403A1). U.H. received speakers and/or advisory board honoraria from Medac, Janssen and Bayer. The remaining authors declare no competing interests.
